Clinical Trial Update: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating talquetamab in participants with relapsed or refractory multiple myeloma; the trial status is active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hematological Malignancies | Phase 1 | Status: ACTIVE_NOT_RECRUITING